

**University of Maryland School of Pharmacy  
Department of Practice, Sciences, and Health Outcomes Research (P-SHOR)  
Pharmaceutical Research Computing (PRC)**

**PRC Data Access Agreement for IQVIA™ Community Database**

Investigator: \_\_\_\_\_

Project Title: \_\_\_\_\_

In order for PRC to provide you with access to IQVIA™ data, it is necessary that you agree to the following provisions:

1. All data and associated project-related files must be maintained and stored in the file folder created by PRC for your approved project and should not be moved to any alternate file folder located in the PRC server environment.
2. Do not place the IQVIA Health data on personal computers, portable devices and removable media. The IQVIA files involve Sensitive Data (e.g. cell size less than 5, percentages or other mathematical formulas that result in the display of a cell 5 or less) that must be protected using encryption software.
3. Assure that PRC is provided with current IRB protocols as well as CITI and HIPAA training certificates.
4. IQVIA Health data are to be used for non-profit, research, and academic study purposes only for the promotion and benefit of public healthcare. When preparing findings:
5. Make no reference to any specific drugs or any specific pharmaceutical, biotechnology or medical device companies in any publication.
6. Use percentages as opposed to dollar amounts in any publication.
7. Do not attempt to re-identify the IQVIA Sensitive Data in any manner.
8. Do not attempt to produce hardcopy documents showing non-aggregated sensitive data.
9. Use the following statement to describe the IQVIA data:  
“The patient cohort used in this study was derived from a 10% random sample of enrollees within the IQVIATM PharMetrics Plus adjudicated claims and enrollment database from 2007-2015.”
10. Use the following statement to reference or source the IQVIA data:  
“The statements, findings, conclusions, views, and opinions contained and expressed in this (insert name or description of the publication, e.g. “in this abstract, article, PPTx”) are based in part on data obtained under license from the following IQVIA™. Source: IQVIA™ PharMetrics Plus January 2007 – December 2015, IQVIA™. All Rights Reserved.” And “The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IQVIA™ or any of its affiliated or subsidiary entities.”
11. Prior to publication, send IQVIA a copy of any proposed publication (electronic or otherwise), and IQVIA shall have at least thirty (30) days thereafter to provide written comment relating thereto prior to such publication. After receipt of IQVIAs’ comments relating to such proposed publication and at least fifteen (15) days prior to any publication, IQVIA is to be presented with a galley proof of the proposed final draft of the publication. Within fifteen (15) days of IQVIAs’ receipt of such proof, IQVIA may provide further comments regarding the draft.

12. If you plan to publish (electronically or otherwise) working papers or similar early previews of the research, send IQVIA a copy of the working papers or previews, and IQVIA shall have at least fifteen (15) days thereafter to provide written comments relating thereto prior to such publication. In the case of electronic (internet) publication, provide IQVIA with an accessible link to the publication.
13. In the event that upon review, IQVIA tags or water-marks the use of Sensitive Data in a manner that allows IQVIA to identify the source of the Sensitive Data, do not attempt to remove or hide any IQVIA data “tags” or “Water-marks”.

Acknowledge and agree that:

14. Data used to conduct this analysis were obtained through a licensed agreement with IQVIA™. PRC is not responsible for the integrity, reliability, or quality of the data secured under this licensed agreement.
15. In the event that any of the above provisions are violated, you will contact PRC within 24 hours to restore compliance with these policies.
16. You will remain in communication with PRC to maintain accurate records and to satisfy PRC’s internal quality control measures.
17. You have read and will abide by the Good Research Practice and Data Security Policies established by the Department of Practice, Sciences, and Health Outcomes Research (P-SHOR) ([https://www.pharmacy.umaryland.edu/media/SOP/wwwpharmacyumarylandedu/centers/prc/pdf/p\\_hsr\\_prc\\_data\\_sec\\_policy.pdf](https://www.pharmacy.umaryland.edu/media/SOP/wwwpharmacyumarylandedu/centers/prc/pdf/p_hsr_prc_data_sec_policy.pdf)).

Signature of Principal Investigator (or individual requesting the use of IQVIA™ PharMetrics Plus data)

Your signature indicates that you agree to comply with the above-stated provisions.

Name: \_\_\_\_\_

Institution: \_\_\_\_\_

Signature: \_\_\_\_\_

Date: \_\_\_\_\_